ReNerve Limited (ASX:RNV)

ReNerve Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Revenue	0.24	0.18	0.13	-
Revenue Growth (YoY)	-	38.04%	-	-
Cost of Revenue	0	0	-	-
Gross Profit	0.24	0.18	0.13	-
Selling, General & Admin	2.62	2.37	1.88	1.27
Research & Development	0.65	0.77	0.3	1.04
Operating Expenses	3.71	3.29	2.32	2.33
Operating Income	-3.47	-3.12	-2.2	-2.33
Interest Expense	-0.52	-0.29	-0.01	-0
Other Non Operating Income (Expenses)	0.57	0.42	0.4	0.58
Pretax Income	-3.41	-2.98	-1.8	-1.76
Net Income	-3.41	-2.98	-1.8	-1.76
Net Income to Common	-3.41	-2.98	-1.8	-1.76
Shares Outstanding (Basic)	142	95	-	-
Shares Outstanding (Diluted)	142	95	-	-
EPS (Basic)	-0.02	-0.03	-	-
EPS (Diluted)	-0.02	-0.03	-	-
Free Cash Flow	-2.68	-2.3	-1.51	-1.98
Free Cash Flow Per Share	-0.02	-0.02	-	-
Gross Margin	98.98%	99.65%	100.00%	-
Operating Margin	-1436.93%	-1756.95%	-1709.17%	-
Profit Margin	-1412.78%	-1682.86%	-1403.39%	-
Free Cash Flow Margin	-1109.00%	-1295.48%	-1178.24%	-
EBITDA	-3.36	-2.97	-2.05	-2.31
D&A For EBITDA	0.11	0.15	0.15	0.02
EBIT	-3.47	-3.12	-2.2	-2.33

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.